Sugi Predict

Sugi Predict / Compounds / SCHEMBL386532

SCHEMBL386532

SCHEMBL386532

Oc1ccc(-c2ccc(Br)cn2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ KDM1A O60341 1/20 0.49
▸ ALOX15 P16050 1/20 0.48
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ STAT3 P40763 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ NFKB1 P19838 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45
▸ RELA Q04206 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ HSD17B1 P14061 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19933574 0.89 NPC1 (0.52) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL8592351 0.88 MEN1 (0.53) MEN1KMT2AKDM1AALOX15NPC1
SCHEMBL1416706 0.87 NPC1 (0.55) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1491731 0.80 NPC1 (0.58) MEN1KMT2AKDM1ANPC1RAB9A
SCHEMBL12523554 0.79 MAPK1 (0.56) NPC1RAB9ASMN1; SMN2NFKB1MAPK1
SCHEMBL28577194 0.79 NPC1 (0.45) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL2319868 0.79 KDM1A (0.49) MEN1KMT2AKDM1ANPC1RAB9A
SCHEMBL31243288 0.79 NPC1 (0.45) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL18555439 0.79 ALDH1A1 (0.48) MEN1KMT2AKDM1AALOX15NPC1
SCHEMBL2649332 0.79 NPC1 (0.53) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025124599-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-06-19 — — WO disclosed
US-20230322826-A1 METAL COMPLEXES UDC IRELAND LIMITED (IE) 2023-10-12 — — US disclosed
US-20230322826-A1 METAL COMPLEXES UDC IRELAND LIMITED (IE) 2023-10-12 — — US disclosed
US-11713332-B2 Metal complexes MERCK PATENT GMBH (DE) 2023-08-01 — — US disclosed
US-11713332-B2 Metal complexes MERCK PATENT GMBH (DE) 2023-08-01 — — US disclosed
US-11031562-B2 Metal complexes MERCK PATENT GMBH (DE) 2021-06-08 — — US disclosed
EP-3484868-B1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2020-11-25 — — EP disclosed
US-20190315787-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2019-10-17 — — US disclosed
WO-2018011186-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2018-01-18 — — WO disclosed
WO-2017032439-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2017-03-02 — — WO disclosed
CN-103998442-B Heterocyclic compound and application thereof 无限药品股份有限公司 2016-09-14 — — CN disclosed
CN-103998442-A Heterocyclic compounds and uses thereof INFINITY PHARMACEUTICALS INC 2014-08-20 — — CN disclosed
CN-101657471-B Bicyclic compounds and their use as antidiabetics SMITHKLINE BEECHAM CORP 2013-07-03 — — CN disclosed
US-20120077812-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS FANG JING (US) 2012-03-29 — — US disclosed
US-8101634-B2 Bicyclic compounds and use as antidiabetics GLAXOSMITHKLINE LLC (US) 2012-01-24 — — US disclosed
EP-2325182-A1 Bicyclic compounds and use as antidiabetics Glaxosmithkline LLC (US) 2011-05-25 — — EP disclosed
CN-101657471-A Bicyclic compounds and their use as antidiabetics SMITHKLINE BEECHAM CORP US 2010-02-24 — — CN disclosed
US-20100029650-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS SMITH KLINE BEECHAM CORPORATION a corporation 2010-02-04 — — US disclosed
EP-2094683-A2 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS SmithKline Beecham Corporation (US) 2009-09-02 — — EP disclosed
WO-2008070692-A2 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS SMITHKLINE BEECHAM CORPORATION (US) 2008-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077812-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS GPR119, GOT2, PC MEN1 3728/4885KMT2A 3867/4885KDM1A 4792/4885
US-20190315787-A1 METAL COMPLEXES AP1M1, SOD1, AP3M1 MEN1 956/4885KMT2A 2971/4885KDM1A 4139/4885
US-11031562-B2 Metal complexes AP1M1, SOD1, AP3M1 MEN1 935/4885KMT2A 2526/4885KDM1A 3794/4885
US-11713332-B2 Metal complexes AP1M1, SOD1, AP3M1 MEN1 956/4885KMT2A 2971/4885KDM1A 4139/4885
US-20230322826-A1 METAL COMPLEXES AP1M1, SOD1, AP3M1 MEN1 956/4885KMT2A 2971/4885KDM1A 4139/4885
US-20100029650-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS GPR119, GOT2, PC MEN1 3728/4885KMT2A 3867/4885KDM1A 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.